Syngene International (SYNGENE) Q1 24/25 earnings summary

Executive summary

• Q1 FY25 revenue from operations was ₹7,897 million, down 2% year-over-year, with operating EBITDA margin declining to 23.3% and reported PAT down 19% to ₹757 million; Discovery Services revenue was impacted by reduced US biotech funding, while Dedicated Centers and Biologics Manufacturing Services showed steady growth.

• The company introduced a new protein production platform to accelerate biologics development and expects momentum to build in H2 FY25, with full-year guidance unchanged.

• Leading indicators such as RFP value increased nearly 50% year-over-year, and multiple pilot projects in discovery services are underway.

Financial highlights

• Q1 FY25 revenue from operations was ₹7,897 million, down 2% year-over-year and 14% sequentially; operating EBITDA margin was 23.3%, down from 28.3% last year.

• PAT before exceptional items was ₹545 million, a 42% decline year-over-year; PAT after exceptional items was ₹757 million, down 19% year-over-year.

• Net cash stood at ₹8,999 million as of June 30, 2024, similar to March 2024.

• Exceptional income of ₹320 million from a past insurance claim was received.

• Basic EPS (consolidated) for Q1 FY25 was ₹1.89, compared to ₹2.33 in Q1 FY24.

Outlook and guidance

• Full-year guidance remains unchanged, with expectations of improved business growth and revenue momentum in H2 FY25.

• EBITDA margin for the full year is expected in the high 20s, with sequential improvement as revenue grows.

• PAT growth for the full year is expected to be in single digits.

• Expansion into manufacturing and changes in depreciation estimates for manufacturing assets are expected to impact future cost and depreciation trends.